Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.

The Journal of pathology - 1 Feb 2008

Preto A, Figueiredo J, Velho S, Ribeiro A S, Soares P, Oliveira C, Seruca R

Abstract excerpt

BRAF kinase is a downstream target of KRAS and activates the MAPK pathway. These two molecules are prone to mutations in sporadic microsatellite unstable (MSI) colorectal carcinomas (CRC) and BRAF V600E mutations are inversely associated with oncogenic KRAS mutations. The biological significance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin D1
Share to Cyclin-Dependent Kinase Inhibitor p27
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Microsatellite Instability

Share to Proto-Oncogene Proteins B-raf

Share to RNA Interference

Share to RNA, Small Interfering

Source

Identifiers

PMID: 18098337
DOI: 10.1002/path.2295

Genes

BRAF
KRAS
XIAP

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18098337-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.PMID 18098337Read ↗

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.Semantic proximity Read ↗

KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis.Semantic proximity Read ↗

BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.Semantic proximity Read ↗

Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Semantic proximity Read ↗

Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.Semantic proximity Read ↗

BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent.Semantic proximity Read ↗

BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms.Semantic proximity Read ↗

Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instabilitySemantic proximity Read ↗

AIM2 Inhibits BRAF-Mutant Colorectal Cancer Growth in a Caspase-1-Dependent MannerSemantic proximity Read ↗

Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.Semantic proximity Read ↗

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.Semantic proximity Read ↗

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.